Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 45:1570-1573, doi:10.1016/j.jacc.2005.01.049
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsagalou, E.
Right arrow Articles by Colombo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsagalou, E.
Right arrow Articles by Colombo, A.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Multiple Overlapping Drug-Eluting Stents to Treat Diffuse Disease of the Left Anterior Descending Coronary Artery

Eleftheria Tsagalou, MD*, Alaide Chieffo, MD*, Ioannis Iakovou, MD{dagger}, Lei Ge, MD{dagger}, Giuseppe M. Sangiorgi, MD{dagger}, Nicola Corvaja, MD{dagger}, Flavio Airoldi, MD*, Matteo Montorfano, MD*, Iassen Michev, MD* and Antonio Colombo, MD, FACC*,{dagger},*

* San Raffaele Hospital, Milan, Italy
{dagger} Columbus Hospital, Milan, Italy

Manuscript received November 24, 2004; revised manuscript received January 18, 2005, accepted January 25, 2005.

* Reprint requests and correspondence: Dr. Antonio Colombo, EMO Centro Cuore Columbus, Via M. Buonarrotti 48, 20145 Milan, Italy (Email: info{at}emocolumbus.it).

OBJECTIVES: We sought to determine the safety and efficacy of using multiple overlapping drug-eluting stents (DES) in patients with diffuse left anterior descending coronary artery (LAD) disease.

BACKGROUND: Diffuse LAD disease represents a therapeutic challenge. Results after coronary artery bypass surgery are suboptimal, whereas the use of bare metal stents is limited by high rates of restenosis. The introduction of DES prompted treatment of long diffuse disease with multiple overlapping stents.

METHODS: All consecutive patients with de novo diffuse LAD disease treated with more than 60-mm long DES from April 2002 to March 2004 were analyzed.

RESULTS: The study population consisted of 66 patients. Thirty-nine patients were treated with sirolimus-eluting stents (SES), average length 84 ± 22 mm, and 27 patients with paclitaxel-eluting stents (PES), average length 74 ± 14 mm. The number of stents implanted per patient was 2.8 ± 0.7, whereas the mean total stent length for the LAD treatment was 80 ± 20 mm. Angiographic as well as procedural success was achieved in 95% of cases. Eleven (16.6%) patients had in-hospital non-Q-wave myocardial infarction (five SES and six PES), and one patient developed intraprocedural stent thrombosis. All patients had clinical follow-up, and 52 patients (79%) had an angiographic follow-up at six months. Hierarchical major adverse cardiac event rate was 15% (7.5% for SES and 7.5% for PES). No patients died, one patient had non-Q-wave myocardial infarction (non-index vessel), and 10 patients (15%) underwent target vessel revascularization.

CONCLUSIONS: The implantation of multiple overlapping DES in patients with a diffusely diseased LAD is relatively safe and associated with good midterm clinical outcomes.

Abbreviations and Acronyms
  BMS = bare-metal stent
  CABG = coronary artery bypass grafting
  DES = drug-eluting stents
  GP = glycoprotein
  LAD = left anterior descending coronary artery
  MACE = major adverse cardiac events
  MI = myocardial infarction
  PES = paclitaxel-eluting stents
  SES = sirolimus-eluting stents
  TIMI = Thrombolysis In Myocardial Infarction




This article has been cited by other articles:


Home page
CirculationHome page
A. Colombo and A. Chieffo
Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Circulation, September 18, 2007; 116(12): 1424 - 1432.
[Full Text] [PDF]


Home page
CirculationHome page
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation, March 20, 2007; 115(11): 1440 - 1455.
[Full Text] [PDF]


Home page
CirculationHome page
Y.-H. Kim, S.-W. Park, S.-W. Lee, D.-W. Park, S.-C. Yun, C. W. Lee, M.-K. Hong, H.-S. Kim, J.-K. Ko, J.-H. Park, et al.
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease
Circulation, November 14, 2006; 114(20): 2148 - 2153.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Thielmann, R. Leyh, P. Massoudy, M. Neuhauser, I. Aleksic, M. Kamler, U. Herold, J. Piotrowski, and H. Jakob
Prognostic Significance of Multiple Previous Percutaneous Coronary Interventions in Patients Undergoing Elective Coronary Artery Bypass Surgery
Circulation, July 4, 2006; 114(1_suppl): I-441 - I-447.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement